Loading market dashboard
BioPorto A/S
THOXFHealthcareOTCDK
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no.
May 12, 2026 News release BioPorto A/S to h ost an investor webcast on the results for the first quarter of 202 6 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO Carsten Buhl and CFO Klaus Juhl Wulff will present financial results for the first quarter of 2026 at a webcast for investors on May 21 , 2026 at 1 1 :00 A M CET . Registration for the presentation is now open, and participants can submit questions in advance.
March 31, 2026 Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA).
26 March 2026 Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: 24 April 2026 at 3.00 p.m.
March 26, 2026 Announcement no. 04 BioPorto announces the Annual Report for 2025 Copenhagen, Denmark, March 26, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no.
March 18, 2026 Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff Study, designed to evaluate the clinical performance of NGAL in assessing risk of acute kidney injury (AKI).
